Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Professor Nicola Curtin.

Newcastle AuthorsTitleYearFull text
Dr Santu Saha
Dr Stuart Rundle
Dr Ioannis Kotsopoulos
Dr Jake Begbie
Rachel Howarth
et al.
Determining the Potential of DNA Damage Response (DDR) Inhibitors in Cervical Cancer Therapy2022
Alice Bradbury
Professor Nicola Curtin
Dr Yvette Drew
The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response2022
Dr Sweta Sharma Saha
Lucy Gentles
Dominik Brecht
Dr Rachel O'Donnell
Professor Nicola Curtin
et al.
Genomic, transcriptomic, and functional alterations in DNA damage response pathways as putative biomarkers of chemotherapy response in ovarian cancer2021
Harriet Southgate
Dr Lindi Chen
Professor Nicola Curtin
Professor Deborah Tweddle
Increased replication stress determines ATR inhibitor sensitivity in neuroblastoma cells2021
Lucy Gentles
Professor Nicola Curtin
Dr Yvette Drew
Dr Rachel O'Donnell
Integration of computer-aided automated analysis algorithms in the development and validation of immunohistochemistry biomarkers in ovarian cancer2021
Dr Christopher Morris
Professor Nicola Curtin
Radiotherapy biobanking: current landscape, opportunities, challenges, and future aspirations2021
Harriet Southgate
Dr Lindi Chen
Professor Deborah Tweddle
Professor Nicola Curtin
ATR inhibition potentiates parp inhibitor cytotoxicity in high risk neuroblastoma cell lines by multiple mechanisms2020
Alice Bradbury
Dr Rachel O'Donnell
Dr Yvette Drew
Professor Nicola Curtin
Dr Sweta Sharma Saha
et al.
Characterisation of ovarian cancer cell line NIH-OVCAR3 and implications of genomic, transcriptomic, proteomic and functional DNA damage response biomarkers for therapeutic targeting2020
Hannah Smith
Harriet Southgate
Professor Deborah Tweddle
Professor Nicola Curtin
DNA damage checkpoint kinases in cancer2020
Hannah Smith
Dr Lisa Prendergast
Professor Nicola Curtin
Exploring the synergy between PARP and CHK1 inhibition in matched BRC2 mutant and corrected cells2020
Professor Nicola Curtin
Poly(ADP-ribose) polymerase inhibition: past, present and future2020
Professor Nicola Curtin
Repositioning PARP inhibitors for SARS-CoV-2 infection (COVID-19); a new multi-pronged therapy for acute respiratory distress syndrome?2020
Alice Bradbury
Sally Hall
Professor Nicola Curtin
Dr Yvette Drew
Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?2020
Harriet Southgate
Dr Lindi Chen
Professor Nicola Curtin
Professor Deborah Tweddle
Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma2020
Professor Nicola Curtin
The development of Rucaparib/Rubraca(R): a story of the synergy between science and serendipity2020
Dr Asima Mukhopadhyay
Dr Yvette Drew
Liz Matheson
Dr Mo Salehan
Lucy Gentles
et al.
Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitors2019
Lucy Gentles
Bojidar Goranov
Elizabeth Matheson
Dr Ashleigh Herriott
Dr Angelika Kaufmann
et al.
Exploring the frequency of Homologous Recombination DNA Repair Dysfunction in Multiple Cancer Types2019
Judith Unterlass
Professor Nicola Curtin
Warburg and Krebs and related effects in cancer2019
Professor Nicola Curtin
Dr Yvette Drew
Dr Sweta Sharma Saha
Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy2019
Lucy Gentles
Liz Matheson
Dr Nicholas Bown
Alice Bradbury
Maryam Zanjirband Zanjirband
et al.
Characterization and drug sensitivity of a novel human overian clear cell carcinoma cell line genomically and phenotypically similar to the original tumor2018
Dr Sarah Fordham
Dr Helen Blair
Dr Claire Elstob
Professor Ruth Plummer
Dr Yvette Drew
et al.
Inhibition of ATR acutely sensitises acute myeloid leukemia cells to nucleoside analogs that target ribonucleotide reductase2018
Professor Nicola Curtin
Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases2018
Fiona Middleton
Professor Nicola Curtin
The impact of p53 dysfunction in ATR inhibitor cytotoxicity and chemo-and radiosensitisation2018
Judith Unterlass
Dr Arnaud Basle
Dr Julie Tucker
Dr Celine Cano
Professor Martin Noble
et al.
Validating and enabling phosphoglycerate dehydrogenase (PHGDH) as a target for fragment-based drug discovery in PHGDH-amplified breast cancer2018
Lucy Gentles
Dr Calum Kirk
Huw Thomas
Professor Steve Wedge
Professor Nicola Curtin
et al.
An investigation of the effect of tissue ischaemia upon DNA damage protein markers in ovarian cancer2017
Maryam Zanjirband Zanjirband
Professor Nicola Curtin
Professor John Lunec
Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer2017
Dr Aiste McCormick
Dr Peter Donoghue
Michelle Dixon
Dr Rachel O'Donnell
James Murray
et al.
Ovarian Cancers Harbour Defects in Non-Homologous End Joining Resulting in Resistance to Rucaparib2017
Dr Miranda Patterson
Dr Yvette Drew
Professor Nicola Curtin
PARP2017
Carlo Bawn
Martin Galler
Huw Thomas
Suzanne Kyle
Professor Nicola Curtin
et al.
PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS2017
Dr Ashleigh Herriott
Dr Miranda Morton
Professor Nicola Curtin
Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers2017
Dr Britta Vormoor
Yvonne Schlosser
Dr Helen Blair
Abhishek Sharma
Sarah Wilkinson
et al.
Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/22017
Professor Nicola Curtin
Strategies Employed for the Development of PARP Inhibitors2017
Judith Unterlass
Dr Arnaud Basle
Dr Julie Tucker
Dr Celine Cano
Professor Martin Noble
et al.
Structural insights into the enzymatic activity and potential substrate promiscuity of human 3-phosphoglycerate dehydrogenase (PHGDH)2017
Dr Ganiy Abdulrahman
Professor Nicola Curtin
Targeting DNA Damage Response Pathways in Cancer2017
Dr Stuart Rundle
Alice Bradbury
Dr Yvette Drew
Professor Nicola Curtin
Targeting the ATR-CHK1 Axis in Cancer Therapy2017
Professor Nicola Curtin
The use of PARP inhibitors in cancer therapy: Use as adjuvant with chemotherapy or radiotherapy, use as a single agent in susceptible patients, and techniques used to identify susceptible patients2017
Dr Rachel O'Donnell
Dr Angelika Kaufmann
Dr Laura Woodhouse
Dr Aiste McCormick
Professor Richard Edmondson
et al.
Advanced Ovarian Cancer Displays Functional Intratumor Heterogeneity That Correlates to Ex Vivo Drug Sensitivity2016
Dr Peter Stephens
Professor Nicola Curtin
Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio-resistance in breast cancer2016
Barry Dent
Laura Ogle
Dr Rachel O'Donnell
Dr Ujjal Mallick
Professor Nicola Curtin
et al.
High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers2016
Laura Ogle
Dr James Orr
Dr Catherine Willoughby
Dr Claire Hutton
Dr Stuart McPherson
et al.
Imagestream detection and characterisation of circulating tumour cells - a liquid biopsy for hepatocellular carcinoma?2016
Dr Ioannis Kotsopoulos
Dr Asima Mukhopadhyay
Professor John Lunec
Professor Nicola Curtin
Ali Kucukmetin
et al.
IN VITRO SINGLE AGENT RUCAPARIB CYTOTOXICITY AND CISPLATIN CHEMO-POTENTIATION IN CERVICAL CANCER CELL LINES2016
Dr Ganiy Abdulrahman
Elizabeth Matheson
Dr Yvette Drew
Professor Nicola Curtin
Dr Asima Mukhopadhyay
et al.
Investigating PARP inhibitor sensitisation by hyperthermia and HSP90 inhibition2016
Dr Peter Stephens
Professor Ruth Plummer
Professor Nicola Curtin
mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition2016
Dr Yvette Drew
Dr Martin Highley
Julieann Sludden
Dr James Murray
Dr David Jamieson
et al.
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly (ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer2016
Dr Ioannis Kotsopoulos
Ali Kucukmetin
Dr Asima Mukhopadhyay
Professor John Lunec
Professor Nicola Curtin
et al.
Poly(ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis Mechanism and Potential Role for PARP Inhibitors2016
Elizabeth Matheson
Dr Mo Salehan
Dr Asima Mukhopadhyay
Professor Nicola Curtin
Dr Yvette Drew
et al.
Preclinical studies of the PARP inhibitor olaparib in combination with imatinib in BRCA stratified ovarian cancer2016
Professor Nicola Curtin
Biomarkers for parp inhibitors2015
Dr Arman Esfandiari
Professor Nicola Curtin
Professor John Lunec
Chemical inhibition or transient knockdown of wild-type p53 induced phosphatase 1 (WIP1/PPM1D) potentiates the response to MDM2 inhibitors in a p53-dependent manner2015
Fiona Middleton
Dr Miranda Morton
Dr Claire Elstob
Dr Sarah Fordham
Dr Ashleigh Herriott
et al.
Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition2015
Dr Aiste McCormick
Dr Peter Donoghue
Michelle Dixon
Dr Rachel O'Donnell
Dr Angelika Kaufmann
et al.
Defects in non-homologous end joining pathway in ovarian cancers results in resistance to rucaparib2015
Dr Tao Chen
Fiona Middleton
Professor Nicola Curtin
Development of pharmacodynamic biomarkers for ATR inhibitors2015
Liam Cornell
Dr Joanne Martin
Laura Ogle
Dr Catherine Willoughby
Dr Despina Televantou
et al.
DNA-PK-A Candidate Driver of Hepatocarcinogenesis and Tissue Biomarker That Predicts Response to Treatment and Survival2015
Dr James Murray
Julieann Sludden
Professor Alan Boddy
Professor Nicola Curtin
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System2015
Dr Britta Vormoor
Yvonne Schlosser
Dr Helen Blair
Sarah Wilkinson
Professor Herbie Newell
et al.
Inhibition of DNA-Repair Enzymes (DNA-Pk and Parp) to Sensitize Ewing Sarcoma to Chemo-And Radiotherapy2015
Dr Rachel O'Donnell
Dr Angelika Kaufmann
Dr Aiste McCormick
Professor Nicola Curtin
Professor Richard Edmondson
et al.
Intra- and inter-tumour heterogeneity in epithelial ovarian cancer: consequences for biomarker dependent stratification of therapies2015
Professor Nicola Curtin
PARP Activity in Peripheral Blood Lymphocytes as a Predictive Biomarker for PARP Inhibition in Tumor Tissues - A Population Pharmacokinetic/Pharmacodynamic Analysis of Rucaparib2015
Dr Ashleigh Herriott
Dr Susan Tudhope
Gesa Junge
Natalie Rodrigues
Dr Miranda Morton
et al.
PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia2015
Dr Aiste McCormick
Dr Sirintra Nakjang
Dr Peter Donoghue
Professor Nicola Curtin
Professor Richard Edmondson
et al.
The role of homologous recombination recovery in cisplatin and rucaparib resistance in ovarian cancer2015
Judith Unterlass
Nabila Aljufri
Sophie Bex
Dr Celine Cano
Professor Martin Noble
et al.
Towards structure-based drug design of 3-phosphoglycerate dehydrogenase inhibitors2015
Fiona Middleton
Dr Tao Chen
Professor Nicola Curtin
Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer2015
Huw Thomas
Professor Nicola Curtin
Vasoactivity of Rucaparib, a PARP-1 Inhibitor, is a Complex Process that Involves Myosin Light Chain Kinase, P2 Receptors, and PARP Itself2015
Dr Miranda Morton
Dr Ian Forrest
Becci Sharrock
Maria Lane
Dr Angelika Kaufmann
et al.
Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples2014
Barry Dent
Dr Rachel O'Donnell
Laura Ogle
Padmini Ramesh
Nick Hayes
et al.
Detection and characterization of circulating tumor cells by imaging flow cytometry2014
Dr Laura Ogle
Dr David Jamieson
Dr Rachel O'Donnell
Barry Dent
Professor Nicola Curtin
et al.
Detection of circulating tumour cells (CTCS) in hepatocellular (HCC) cancer patients using the ImageStreamx2014
Wojciech Ciszewski
Dr Michele Tavecchio
Professor Nicola Curtin
DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin2014
Dr Asima Mukhopadhyay
Michelle Dixon
Dr Evan Mulligan
James Murray
Professor Nicola Curtin
et al.
Evaluation of different methods to assess homologous recombination status and sensitivity to parp inhibitors in ovarian cancer2014
Dr Stephany Veuger
Professor Nicola Curtin
Inhibition of DNA Repair as a Therapeutic Target2014
Fiona Middleton
Dr Tao Chen
Professor Nicola Curtin
Investigating p53 and other potential determinants of cell sensitivity to ATR inhibition by VE-8212014
Professor Nicola Curtin
Professor Rakesh Heer
Investigating PARP-1 expression and activity in male and female, benign and malignant renal tissue2014
Professor Richard Edmondson
Dr Asima Mukhopadhyay
Professor Nicola Curtin
Molecular characterization of matched ovarian ascites and tumors suggests multiple mechanisms for a homologous recombination defective phenotype2014
Fiona Middleton
Dr Tao Chen
Professor Nicola Curtin
p53 and other components of the DNA damage response as determinants of cell sensitivity to ATR inhibition2014
Professor Nicola Curtin
PARP inhibitors for anticancer therapy2014
Professor Nicola Curtin
PARP inhibitors target ATM+p53-defective gastric cancer2014
Dr Britta Vormoor
Professor Nicola Curtin
Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma2014
Pawel Znojek
Dr Elaine Willmore
Professor Nicola Curtin
Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase2014
Dr Rachel O'Donnell
Dr Aiste McCormick
Dr Asima Mukhopadhyay
Michelle Dixon
Dr Angelika Kaufmann
et al.
The Use of Ovarian Cancer Cells from Patients Undergoing Surgery to Generate Primary Cultures Capable of Undergoing Functional Analysis2014
James Murray
Huw Thomas
Philip Berry
Suzanne Kyle
Dr Miranda Morton
et al.
Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules2014
Dr Celine Cano
Dr Kappusamy Saravanan
Professor Nicola Curtin
Professor Bernard Golding
Dr Ian Hardcastle
et al.
1-Substituted (Dibenzo[b,d]thiophen-4-yl)-2-morpholino-4H-chromen-4-ones Endowed with Dual DNA-PK PI3-K Inhibitory Activity2013
Professor Ruth Plummer
Dr Evan Mulligan
Professor Nicola Curtin
Professor Alan Calvert
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation2013
Anna Whitehead
Dr Gillian Patman
Liam Cornell
Dr Despina Televantou
Professor Nicola Curtin
et al.
A Role for DNA Repair Protein Kinase (DNA-PK) in the Progression of Simple Steatosis to Steatohepatitis (NASH)?2013
Fiona Middleton
Professor Nicola Curtin
ATR as a therapeutic target2013
Professor Nicola Curtin
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer2013
Dr Tommy Rennison
Sonsoles Rodriguez-Aristegui
Professor Nicola Curtin
Professor Bernard Golding
Dr Ian Hardcastle
et al.
Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK)2013
Professor Nicola Curtin
First-in-human trial of novel oral PARP inhibitor BMN 673 in patients with solid tumors2013
Dr Rachel O'Donnell
Laura Woodhouse
Dr Aiste McCormick
Dr Asima Mukhopadhyay
Michelle Dixon
et al.
Functional Intra-Tumour Heterogeneity in Ovarian Cancer: What is a Representative Tumour Sample?2013
Professor Nicola Curtin
Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer2013
Dr Aiste McCormick
Professor Nicola Curtin
Professor Richard Edmondson
Inhibition of DNA-PK Recovers HR Function and Results in Platinum Resistance in an Ovarian Cancer Cell Line Model2013
Dr Miranda Morton
Professor Nicola Curtin
Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies2013
Michael Batey
Dr Yan Zhao
Suzanne Kyle
Professor Herbie Newell
Professor Nicola Curtin
et al.
Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer2013
Dr Rachel O'Donnell
Barry Dent
Laura Ogle
Professor Nicola Curtin
Dr David Jamieson
et al.
The Characterisation and Functional Assessment of Epithelial Ovarian Cancer Cells Derived from Ascitic Fluid using Imagestream2013
Professor Nicola Curtin
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond2013
Fiona Middleton
Dr Tao Chen
Professor Nicola Curtin
Chemosensitisation By, and Single Agent Activity of, ATR Inhibitor VE-821 in Human Breast Cancer Cells2012
Dr Joanne Martin
Michael Batey
Dr Yan Zhao
Dr Celine Cano
Dr Michele Tavecchio
et al.
Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K2012
Dr Asima Mukhopadhyay
Professor Ruth Plummer
Dr Ahmed Elattar
Dr San Soo Hoo
Bisha Uzir
et al.
Clinicopathological features of homologous recombination deficient epithelial ovarian cancers: Sensitivity to PARP inhibitors, platinum and survival2012
Dr Asima Mukhopadhyay
Professor Ruth Plummer
Dr Ahmed Elattar
Dr San Soo Hoo
Bisha Uzir
et al.
Clinicopathological features of homologous recombination deficient epithelial ovarian cancers: Sensitivity to PARP inhibitors, platinum and survival2012
Dr Asima Mukhopadhyay
Professor Ruth Plummer
Dr Ahmed Elattar
Dr San Soo Hoo
Bisha Uzir
et al.
Clinicopathological Features of Homologous Recombination-Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival2012
Dr Aiste McCormick
Dr Asima Mukhopadhyay
Professor Ruth Plummer
Professor Nicola Curtin
Professor Richard Edmondson
et al.
Defective homologous recombination in human cancers2012
Professor Nicola Curtin
DNA repair dysregulation from cancer driver to therapeutic target2012
Liam Cornell
Dr Joanne Martin
Professor Nicola Curtin
Professor Helen Reeves
DNA-PK or ATM inhibition inhibits non-homologous end joining and enhances chemo- and radio sensitivity in hepatocellular cancer cell lines2012
Dr Britta Vormoor
Sarah Wilkinson
Fiona Harvey
Professor Ruth Plummer
Professor Nicola Curtin
et al.
Ewing's Sarcoma Cells Can Be Sensitized to Temozolomide and to a Lesser Extent to Radiotherapy by Co-treatment with a PARP-inhibitor (AG014699)2012
Dr Michele Tavecchio
Dr Joanne Martin
Dr Celine Cano
Professor Herbie Newell
Professor Nicola Curtin
et al.
Further characterisation of the cellular activity of the DNA-PK inhibitor, NU7441, reveals potential cross-talk with homologous recombination2012
Dr Elaine Willmore
Natalie Rodrigues
Dr Jonathan Wallis
Professor Nicola Curtin
High Activity of Poly(ADP-Ribose) Polymerase in Chronic Lymphocytic Leukemia2012
Dr Aiste McCormick
Professor Nicola Curtin
Professor Richard Edmondson
Non homologous end joining assessment in ovarian cancer2012
Professor Nicola Curtin
Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors2012
Dr Miranda Morton
James Murray
Professor Nicola Curtin
Stability of PARP Inhibition by BMN 673 in Human PBMCs (and Leukaemic Cell Cultures)2012
Dr Tao Chen
Dr Peter Stephens
Fiona Middleton
Professor Nicola Curtin
Targeting the S and G2 checkpoint to treat cancer2012
Professor Nicola Curtin
The use of PARP inhibitors in cancer therapy: use as adjuvant with chemotherapy or radiotherapy; use as a single agent in susceptible patients; techniques used to identify susceptible patients2012
Professor Nicola Curtin
Triple negative breast cancer: proposals for a pragmatic definition and implications for patient management and trial design2012
Dr Jody Barbeau
Professor Nicola Curtin
Visualization of a DNA-PK/PARP1 complex2012
Huw Thomas
Professor Herbie Newell
Professor Nicola Curtin
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition2011
Dr Amy Peasland
Dr Tao Chen
Professor Richard Edmondson
Professor Nicola Curtin
Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines2011
Dr Kappusamy Saravanan
Hannah Barlow
Marion Barton
Professor Hilary Calvert
Professor Bernard Golding
et al.
Nucleoside Transport Inhibitors: Structure-Activity Relationships for Pyrimido[5,4-d]pyrimidine Derivatives That Potentiate Pemetrexed Cytotoxicity in the Presence of α1-Acid Glycoprotein2011
Dr Asima Mukhopadhyay
Professor Nicola Curtin
Professor Ruth Plummer
Professor Richard Edmondson
PARP Inhibitors And Epithelial Ovarian Cancer: An Approach To Targeted Chemotherapy And Personalized Medicine2011
Tomasz Zaremba
Huw Thomas
Mike Cole
Dr Sally Coulthard
Professor Ruth Plummer
et al.
Poly(ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers2011
Huw Thomas
Dr Celine Roche
Dr Johanne Bentley
Dr Ian Hardcastle
Professor Bernard Golding
et al.
Preclinical in vitro and in vivo evaluation of the potent and specific cyclin-dependent kinase 2 inhibitor NU6102 and a water soluble prodrug NU63012011
Professor Nicola Curtin
Strategies employed for the development of PARP inhibitors2011
Dr Fadhel Shaheen
Pawel Znojek
Dr Ann Fisher
Professor Ruth Plummer
Dr Luke Gaughan
et al.
Targeting the DNA Double Strand Break Repair Machinery in Prostate Cancer2011
Huw Thomas
Suzanne Kyle
Ivanda Pavlovska
Professor Nicola Curtin
The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice2011
Professor Nicola Curtin
The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy2011
Professor Nicola Curtin
The role of PARP in DNA repair and its therapeutic exploitation2011
Dr Yvette Drew
Dr Evan Mulligan
Wan Vong
Huw Thomas
Suzanne Kyle
et al.
Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA22011
Huw Thomas
Suzanne Kyle
Rafal Zur
Dr Evan Mulligan
Professor Nicola Curtin
et al.
6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance2010
Rachel Daniel
Dr Agata Rozanska
Dr Evan Mulligan
Dr Yvette Drew
Huw Thomas
et al.
Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-0146992010
Dr Asima Mukhopadhyay
Dr Ahmed Elattar
Dr Aiste McCormick
Sarah Wilkinson
Dr Yvette Drew
et al.
Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors2010
Dr Kate Smith
Dr Tommy Rennison
Sonsoles Rodriguez-Aristegui
Professor Nicola Curtin
Professor Bernard Golding
et al.
Development of potent inhibitors of DNA-dependent protein kinase (DNA-PK)2010
Dr Celine Cano
Olivier Barbeau
Professor Nicola Curtin
Professor Bernard Golding
Dr Ian Hardcastle
et al.
DNA-Dependent Protein Kinase (DNA-PK) Inhibitors. Synthesis and Biological Activity of Quinolin-4-one and Pyridopyrimidin-4-one Surrogates for the Chromen-4-one Chemotype2010
Tomasz Zaremba
Huw Thomas
Mike Cole
Professor Ruth Plummer
Professor Nicola Curtin
et al.
Doxorubicin-induced suppression of poly(ADP-ribose) polymerase-1 (PARP-1) activity and expression and its implication for PARP inhibitors in clinical trials2010
Dr Nicola Johnson
Dr Johanne Bentley
Lan Wang
Professor Herbie Newell
Professor Craig Robson
et al.
Pre-clinical evaluation of cyclin-dependent kinase 2 and 1 inhibition in anti-estrogen-sensitive and resistant breast cancer cells2010
Dr Britta Vormoor
Professor Nicola Curtin
Professor Steven Clifford
Sensitisation of paediatric solid tumours to DNA-damaging chemotherapy by inhibition of DNA-dependent protein kinase (PRKDC)2010
Dr Francesco Marchetti
Dr Celine Cano
Professor Nicola Curtin
Professor Bernard Golding
Professor Roger Griffin
et al.
Synthesis and biological evaluation of 5-substituted O4-alkylpyrimidines as CDK2 inhibitors2010
Liam Cornell
Dr Joanne Martin
Febrina Budhisetiawan
Professor Herbie Newell
Professor Derek Manas
et al.
Synthetic lethality in liver cancer cell lines treated with inhibitors of DNA double strand break repair2010
Dr Agata Rozanska
Dr Evan Mulligan
Huw Thomas
Deborah Castelbuono
Professor Deborah Tweddle
et al.
[abstract] Central nervous system (CNS) penetration, poly-ADP ribose polymerase (PARP) inhibition and enhancement of temozolomide activity against childhood medulloblastoma by AG-0146992009
Professor Nicola Curtin
[abstract] Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked2009
Dr Evan Mulligan
Tomasz Zaremba
Dr Yvette Drew
Professor Ruth Plummer
Professor Nicola Curtin
et al.
[abstract] Validated sensitive immunological determination of PARP-1 protein levels and activity in cultured cells and human lymphocytes2009
Dr Evan Mulligan
Professor Nicola Curtin
Professor Ruth Plummer
Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines2009
Huw Thomas
Professor Nicola Curtin
Exploiting Homologous recombination repair defects in cancer cells2009
Dr Agata Rozanska
Huw Thomas
Dr Evan Mulligan
Dr Yvette Drew
Deborah Castelbuono
et al.
Inhibition of Poly (ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood Neuroblastoma2009
Professor Nicola Curtin
Poly(ADP-Ribose) Polymerase-1 and DNA-Dependent Protein Kinase Have Equivalent Roles in Double Strand Break Repair Following Ionizing Radiation2009
Tomasz Zaremba
Professor Ruth Plummer
Dr Sally Coulthard
Mike Cole
Professor Nicola Curtin
et al.
Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in a panel of human tumor cell lines [abstract]2009
Tomasz Zaremba
Mike Cole
Dr Sally Coulthard
Professor Ruth Plummer
Professor Nicola Curtin
et al.
Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines2009
Huw Thomas
Dr Kappusamy Saravanan
Lan Wang
Mei Lin
Dr Julian Scott Northen
et al.
Preclinical evaluation of a novel pyrimidopyrimidine for the prevention of nucleoside and nucleobase reversal of antifolate cytotoxicity2009
Huw Thomas
Suzanne Kyle
Tim Robson
Professor Nicola Curtin
Vasoactivity of AG014699, a Clinically Active Small Molecule Inhibitor of Poly(ADP-ribose) Polymerase: a Contributory Factor to Chemopotentiation In vivo?2009
Professor Herbie Newell
Huw Thomas
Lan Wang
Dr Celine Roche
Dr Ian Hardcastle
et al.
[abstract] Preclinical in vitro and in vivo evaluation of the cyclin dependent kinase 2 inhibitor NU6102 and a water pro-drug NU63012008
Neil Johnson
Professor Nicola Curtin
Dr Andrew Hall

A comparative study of genome-wide SNP, CGH microarray and protein expression analysis to explore genotypic and phenotypic mechanisms of acquired antiestrogen resistance in breast cancer

2008
Dr Celine Cano
Professor Bernard Golding
Dr Ian Hardcastle
Professor Nicola Curtin
Professor Roger Griffin
et al.
8-Biarylchromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK)2008
Huw Thomas
Professor Nicola Curtin
Chemosensitisation by tricyclic poly(ADP-ribose) polymerase (PARP) inhibitors in vivo: More than just DNA repair? [abstract]2008
Michael Batey
Professor Herbie Newell
Professor Nicola Curtin
Chemosensitisation of cancer cells by KU-0060648, a potent and selective inhibitor of DNA-PK [abstract]2008
Dr Celine Cano
Professor Nicola Curtin
Professor Bernard Golding
Dr Karen Haggerty
Dr Ian Hardcastle
et al.
Development of Potent Water-soluble Inhibitors of DNA-Dependent Protein Kinase (DNA-PK)2008
Suzanne Kyle
Huw Thomas
Dr Jane Mitchell
Professor Nicola Curtin
Exploiting the Achilles heel of cancer: the therapeutic potential of poly(ADP-ribose) polymerase inhibitors in BRCA2-defective cancer2008
Dr Kappusamy Saravanan
Dr Celine Cano
Professor Nicola Curtin
Professor Bernard Golding
Dr Karen Haggerty
et al.
Identification of potent water-soluble DNA-dependent protein kinase (DNA-PK) inhibitors using a small-molecule library approach [abstract]2008
Dr Yvette Drew
Suzanne Kyle
Professor Richard Edmondson
Professor Ruth Plummer
Professor Nicola Curtin
et al.
Investigating DNA double strand break formation and repair in response to the PARP inhibitor AG014699 in cell lines defective in Homologous Recombination: a role for PARP inhibitors in sporadic cancers? [abstract]2008
Professor Alan Calvert
Professor Ruth Plummer
Professor Nicola Curtin
Professor Richard Edmondson
Dr Yvette Drew
et al.
PARP inhibitors in cancer treatment2008
Professor Alan Calvert
Professor Nicola Curtin
Professor Ruth Plummer
PARP inhibitors in ovarian cancer2008
Professor Ruth Plummer
Dr Christopher Jones
Professor Nicola Curtin
Professor Alan Boddy
Professor Herbie Newell
et al.
Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors2008
Tomasz Zaremba
Mike Cole
Dr Sally Coulthard
Professor Ruth Plummer
Professor Nicola Curtin
et al.
Poly(ADP-ribose) polymerase-1 (PARP-1) genomics in relation to activity in healthy volunteers and cancer patients2008
Michael Batey
Dr Laurent Rigoreau
Professor Roger Griffin
Professor Herbie Newell
Professor Nicola Curtin
et al.
Potent in vitro and in vivo radiosensitisation by the selective DNA-dependent protein kinase inhibitor KU-0060648 [abstract]2008
Professor Nicola Curtin
Rationale for and development of PARP inhibitors for cancer therapy2008
Lan Wang
Professor Nicola Curtin
Professor Herbie Newell
Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked2008
Tomasz Zaremba
Professor Nicola Curtin
PARP inhibitor development for systemic cancer targeting2007
Professor Steven Clifford
Rachel Daniel
Dr Agata Rozanska
Huw Thomas
Professor Alan Boddy
et al.
Preclinical evaluation of the POLY-ADP ribose polymerase 1 (PARP-1) inhibitor AG014699 in combination with topotecan and temozolomide for the treatment of medulloblastoma and neuroblastoma2007
Huw Thomas
Dr Christopher Calabrese
Michael Batey
Suzanne Kyle
Professor Herbie Newell
et al.
Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial2007
Jonathan Hollick
Dr Laurent Rigoreau
Dr Celine Cano
Professor Nicola Curtin
Professor Bernard Golding
et al.
Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase2007
Dr Francesco Marchetti
Kerry Louise Sayle
Dr Johanne Bentley
Emeritus Professor Bill Clegg
Professor Nicola Curtin
et al.
Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6- aminopyrimidine inhibitors of cyclin-dependent kinase 22007
Dr Anastasia Hepburn
Professor Craig Robson
Professor Nicola Curtin
Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer2007
Professor Nicola Curtin
Therapeutic potential of drugs to modulate DNA repair in cancer2007
Huw Thomas
Dr Christopher Calabrese
Professor Herbie Newell
Lan Wang
Professor Nicola Curtin
et al.
Identification of a PARP inhibitor for clinical trial: Preclinical studies2006
Dr Yan Zhao
Huw Thomas
Michael Batey
Dr Ian Cowell
Professor Roger Griffin
et al.
Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU74412006
Professor Roger Griffin
Andrew Henderson
Professor Nicola Curtin
Professor Jane Endicott
Dr Ian Hardcastle
et al.
Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination2006
Dr Ian Hardcastle
Professor Nicola Curtin
Justin John James Leahy
Martin Stockley
Professor Bernard Golding
et al.
Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach2005
Professor Herbie Newell
Professor Roger Griffin
Richard Davison
Lan Wang
Professor Nicola Curtin
et al.
Effect of cell cycle inhibition on cisplatin-induced cytotoxicity2005
Professor Ruth Plummer
Professor Alan Boddy
Professor Nicola Curtin
Professor Herbie Newell
Lynsey Robson
et al.
Final clinical, pharmacokinetic and pharmacodynamic results of the phase I study of the novel poly(ADP-ribose)polymerase (PARP) inhibitor, AG014699, in combination with temozolomide2005
Dr Ian Hardcastle
Dr Shafiq Ahmed
Professor Alan Calvert
Professor Nicola Curtin
Gillian Farnie
et al.
Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction2005
Professor Nicola Curtin
PARP inhibitors for cancer therapy2005
Professor Nicola Curtin
PARP inhibitors for cancer therapy2005
Professor Roger Griffin
Dr YuZhu Cheng
Professor Nicola Curtin
Professor Bernard Golding
Dr Ian Hardcastle
et al.
Potent CDK2 inhibitors generated using a variant of the cope elimination2005
Dr Allyson Campbell
Dr YuZhu Cheng
Lan Wang
Professor Nicola Curtin
Professor Bernard Golding
et al.
Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: A possible role for survivin down-regulation2005
Andrew Henderson
Dr YuZhu Cheng
Professor Nicola Curtin
Professor Bernard Golding
Professor Roger Griffin
et al.
Searching for potent CDK2 inhibitors using a variant of the Cope elimination2005
Huw Thomas
Kathleen Parker
Suzanne Kyle
Professor Nicola Curtin
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase2005
Professor Ruth Plummer
Dr Christopher Jones
Professor Alan Boddy
Professor Alan Calvert
Professor Herbie Newell
et al.
Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-12005
Lisa Smith
Dr Elaine Willmore
Professor Caroline Austin
Professor Nicola Curtin
The novel poly(ADP-ribose) polymerase inhibitor, AG14361 sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks2005
Dr Jane Mitchell
Professor Nicola Curtin
The role of PARP-1 and DNA-PK in the repair of DNA double strand breaks2005
Dr Christopher Calabrese
Michael Batey
Professor Alan Calvert
Professor barbara Durkacz
Suzanne Kyle
et al.
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG143612004
Dr Christopher Calabrese
Professor Nicola Curtin
Suzanne Kyle
Huw Thomas
Lan Wang
et al.
Design, synthesis, and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1- hi]indol-1-ones as inhibitors of poly(ADP-ribose) polymerase2004
Dr Stephany Veuger
Professor Nicola Curtin
Professor barbara Durkacz
Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair2004
Dr Stephany Veuger
Professor Nicola Curtin
Professor barbara Durkacz
Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair2004
Dr Yan Zhao
Dr Susan Jackson
Professor Nicola Curtin
Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM2004
Dr Ian Hardcastle
Dr Christine Arris
Dr Johanne Bentley
Professor Nicola Curtin
Professor Jane Endicott
et al.
N2-substituted O6-cyclohexylmethylguanine derivatives: Potent inhibitors of cyclin-dependent kinases 1 and 22004
Professor Nicola Curtin
Lan Wang
Suzanne Kyle
Dr Christine Arris
Professor barbara Durkacz
et al.
Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells2004
Professor Nicola Curtin
Professor Bernard Golding
Suzanne Kyle
Professor Roger Griffin
Potentiation of cytotoxic drug activity in human tumour cell lines, by amine-substituted 2-arylbenzimidazole-4-carboxamide PARP-1 inhibitors2004
Professor Nicola Curtin
Hannah Barlow
Professor Alan Calvert
Richard Davison
Professor Bernard Golding
et al.
Resistance-modifying agents. 11. Pyrimido[5,4-d]pyrimidine modulators of antitumor drug activity. Synthesis and structure-activity relationships for nucleoside transport inhibition and binding to α1-acid glycoprotein2004
Dr Nicola Johnson
Professor Nicola Curtin
The effects of a novel CDK inhibitor on tamoxifen sensitive and resistant breast cancer cell lines2004
Dr Veronique Mesguiche
Rachel Parsons
Dr Christine Arris
Dr Johanne Bentley
Professor Nicola Curtin
et al.
4-Alkoxy-2,6-diaminopyrimidine derivatives: Inhibitors of cyclin dependent kinases 1 and 22003
Dr Christopher Calabrese
Michael Batey
Huw Thomas
Professor barbara Durkacz
Lan Wang
et al.
Identification of potent nontoxic poly(ADP-ribose) polymerase-1 inhibitors: Chemopotentiation and pharmacological studies2003
Dr Stephany Veuger
Professor Nicola Curtin
Professor barbara Durkacz
Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-12003
Kerry Louise Sayle
Dr Johanne Bentley
Professor Alan Calvert
Dr YuZhu Cheng
Professor Nicola Curtin
et al.
Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 22003
Professor Nicola Curtin
Professor Herbie Newell
Professor Alan Calvert
Professor Roger Griffin
Professor Bernard Golding
et al.
Tricyclic benzimidazoles as potent poly(ADP-ribose) polymerase-1 inhibitors2003
Dr Julian Scott Northen
Emeritus Professor Bill Clegg
Professor Nicola Curtin
Professor Roger Griffin
Professor Bernard Golding
et al.
Controlled stepwise conversion of 2,4,6,8-tetrachloropyrimido-[5,4-d ]pyrimidine into 2,4,6,8-tetrasubstituted pyrimido[5,4-d]pyrimidines2002
Noel Monks
Professor Nicola Curtin
Dr Christine Arris
Professor Herbie Newell
DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD27672002
Dr Christopher Calabrese
Professor Nicola Curtin
Suzanne Kyle
Huw Thomas
Lan Wang
et al.
Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: Design, synthesis, and X-ray cocrystal structure2002
Dr Ashleigh Gibson
Dr Christine Arris
Dr Johanne Bentley
Professor Nicola Curtin
Professor Jane Endicott
et al.
Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O6-substituted guanine derivatives2002
Dr Johanne Bentley
Dr Christine Arris
Professor Nicola Curtin
Professor Jane Endicott
Dr Ashleigh Gibson
et al.
Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor2002
Dr Elaine Willmore
Professor Caroline Austin
Professor Nicola Curtin
The role of poly(ADP-ribose) polymerase-1 (PARP-1) in the cellular response to topoisomerase I poisons2002
Dr Xiaomei Lu
Julie Errington
Professor Nicola Curtin
Professor John Lunec
Professor Herbie Newell
et al.

The impact of p53 status on cellular sensitivity to antifolate drugs

2001
Professor Nicola Curtin
Dr Stephen Barton
Michael Batey
Dr Christopher Calabrese
Professor Alan Calvert
et al.
Anti-cancer chemosensitization in vitro and in vivo by a novel potent poly(ADP-ribose) polymerase (PARP1) inhibitor, TBI-361.2001
Professor Herbie Newell
Professor Alan Calvert
Professor Nicola Curtin
Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro2001
Gordon Taylor
Huw Thomas
Professor Herbie Newell
Professor Nicola Curtin
Hypoxanthine transport in human tumour cell lines. Relationship to the inhibition of hypoxanthine rescue by dipyridamole2001
Peter Smith
Huw Thomas
Hannah Barlow
Professor Roger Griffin
Professor Bernard Golding
et al.
In vitro and in vivo properties of novel nucleoside transport inhibitors with improved pharmacological properties that potentiate antifolate activity2001
Noel Monks
Professor Nicola Curtin
Professor Herbie Newell
Induction of apoptosis by the ADEPT agent ZD2767: Comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue2001
Professor Alan Calvert
Professor Nicola Curtin
Professor Bernard Golding
Professor Roger Griffin
Dr Ian Hardcastle
et al.
Inhibiting the MDM2-p53 interaction using low molecular weight compounds2001
Professor Nicola Curtin
Dr Andrew Hughes
Pemetrexed disodium, a novel antifolate with multiple targets2001
Dr Stephany Veuger
Professor barbara Durkacz
Professor Bernard Golding
Professor Roger Griffin
Professor Herbie Newell
et al.
Radiosensitization by novel inhibitors of PARP, PI, and DNA-PK, NU7026, in vitro2001
Professor Martin Noble
Dr Christine Arris
Professor Alan Calvert
Professor Nicola Curtin
Dr Ashleigh Gibson
et al.
Structural and thermodynamic validation of inactive cdk2 as a template for structure-based drug design2001
Professor Martin Noble
Dr Christine Arris
Professor Alan Calvert
Professor Nicola Curtin
Professor Bernard Golding
et al.
Structure based design of a potent inhibitor of cdk22001
Lan Wang
Professor Nicola Curtin
Professor Herbie Newell
Tumor radiosensitization using TBI-361, an inhibitor of poly (ADP-ribose) polymerase (PARP)2001
Peter Smith
Huw Thomas
Hannah Barlow
Professor Roger Griffin
Professor Bernard Golding
et al.
In vitro activity and in vivo pharmacology of two novel nucleoside transport inhibitors, NU3108 and NU31212000
Dr Xiaohong Lu
Julie Errington
Professor Nicola Curtin
Professor Alan Boddy
Professor Herbie Newell
et al.
Cellular ATP depletion by LY309887 as a predictor of growth inhibition in human tumor cell lines2000
Noel Monks
Professor Nicola Curtin
Professor Herbie Newell
Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT)2000
Professor Nicola Curtin
Professor Alan Calvert
Professor barbara Durkacz
Professor Roger Griffin
Professor Bernard Golding
et al.
Chemopotentiation studies with two classes of potent (polyADP-ribose) polymerase (PARP) inhibitors in human lung and colon carcinoma cell lines.2000
Dr Christopher Calabrese
Professor Nicola Curtin
Michael Batey
Huw Thomas
Suzanne Kyle
et al.
Design and evaluation of novel potent inhibitors of poly (ADP-ribose) polymerase2000
Professor Roger Griffin
Dr Christine Arris
Professor Alan Calvert
Professor Nicola Curtin
Dr Ashleigh Gibson
et al.
Design, synthesis, and biological evaluation of O-6-alkylguanine and O-4-alkylpyrimidine cyclin-dependent kinase inhibitors2000
Peter Smith
Professor Herbie Newell
Professor Nicola Curtin
Dipyridamole potentiates the in vitro activity of MTA (LY231514) by inhibition of thymidine transport2000
Dr Christine Arris
Professor Alan Calvert
Professor Nicola Curtin
Dr Ashleigh Gibson
Professor Bernard Golding
et al.
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles2000
Dr Christine Arris
Professor Alan Calvert
Professor Nicola Curtin
Professor Jane Endicott
Professor Bernard Golding
et al.
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles2000
Dr Christine Arris
Professor Alan Calvert
Professor Nicola Curtin
Professor Bernard Golding
Professor Roger Griffin
et al.
O6-substituted guanines and 4-substituted pyrimidines: a novel class of antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.2000
Lan Wang
Suzanne Kyle
Alex White
Professor Alan Calvert
Professor Nicola Curtin
et al.
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines2000
Professor Roger Griffin
Dr Christine Arris
Dr Christine Bleasdale
Professor Alan Calvert
Professor Nicola Curtin
et al.
Resistance-modifying agents. 8. Inhibition of O6-alkylguanine-DNA alkyltransferase by O6-alkenyl-, O6-cycloalkenyl-, and O6-(2-oxoalkyl)guanines and potentiation of temozolomide cytotoxicity in vitro by O6-(1-cyclopentenylmethyl) guanine2000
Alex White
Professor Alan Calvert
Professor Nicola Curtin
Professor Roger Griffin
Professor Herbie Newell
et al.
Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase2000
Hannah Barlow
Professor Nicola Curtin
Professor Alan Calvert
Professor Bernard Golding
Professor Herbie Newell
et al.
Resistance-modifying agents. Part 7: 2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines that inhibit nucleoside transport in the presence of α1-acid glycoprotein (AGP)2000
Dr Johanne Bentley
Dr Christine Arris
Professor Alan Calvert
Professor Nicola Curtin
Professor Jane Endicott
et al.
Structure-activity relationships and cellular effects of novel purine- and pyrimidine-based cyclin dependent kinase inhibitors2000
Professor Roger Griffin
Hannah Barlow
Professor Nicola Curtin
Professor Alan Calvert
Professor Bernard Golding
et al.
2,6-Disubstituted-4,8-dibenzylaminopyrimido[5,4-d]pyrimidines as nucleoside transport inhibitors: Structure-activity relationships for binding to alpha(1)-acid glycoprotein (AGP)1999
Professor Herbie Newell
Dr Christine Arris
Professor Alan Calvert
Professor Nicola Curtin
Dr Ashleigh Gibson
et al.
Antiproliferative cyclin dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.1999
Professor Nicola Curtin
Dr David Turner
Dipyridamole-mediated reversal of multidrug resistance in MRP over- expressing human lung carcinoma cells in vitro1999
Dr Christine Arris
Professor Alan Calvert
Professor Nicola Curtin
Dr Ashleigh Gibson
Professor Bernard Golding
et al.
In vitro growth activity of novel purine- and pyrimidine-based CDK1 and CDK2 inhibitors.1999
Peter Smith
Professor Alan Calvert
Professor Herbie Newell
Professor Nicola Curtin
MTA (LY231514) induced intracellular dNTP pool pertubations are alleviated by salvage of pre-formed purines and pyrimidines1999
Peter Smith
Hannah Barlow
Professor Alan Calvert
Professor Nicola Curtin
Professor Bernard Golding
et al.
Novel dipyridamole analogues potentiate the in vitro activity of MTA (LY231514) in the presence of alpha(1)-acid glycoprotein.1999
Professor Nicola Curtin
Professor Alan Calvert
Professor barbara Durkacz
Professor Herbie Newell
Potentiation of temozolomide and topotecan cytotoxicity by PARP inhibitors in a panel of human cancer cell lines.1999
Professor Nicola Curtin
Suzanne Kyle
Lan Wang
Professor barbara Durkacz
Professor Roger Griffin
et al.
Potentiation of temozolomide and topotecan growth inhibition by novel potent benzimidazole poly(ADP-ribose) polymerase (PARP) inhibitors1999
Professor Nicola Curtin
Professor Alan Calvert
Professor Bernard Golding
Professor Roger Griffin
Professor Herbie Newell
et al.
Potentiation of the cytotoxicity of thymidylate synthase (TS) inhibitors by dipyridamole analogues with reduced α1-acid glycoprotein binding1999
Dr Christopher Calabrese
Huw Thomas
Michael Batey
Professor Nicola Curtin
Professor Roger Griffin
et al.
Preclinical pharmacology of novel substituted benzimidazoles - potent inhibitors of poly (ADP-ribose) polymerase1999
Peter Smith
Professor Alan Calvert
Professor Herbie Newell
Professor Nicola Curtin
Prevention of thymidine and hypoxanthine rescue from MTA (LY231514) growth inhibition by dipyridamole in human lung cancer cell lines1999
Professor Alan Calvert
Professor Nicola Curtin
Professor Bernard Golding
Professor Roger Griffin
Professor Herbie Newell
et al.
2-phenylbenzimidazole-4-carboxamides are potent inhibitors of the DNA repair enzyme poly(ADP-ribose)-polymerase (PARP)1998
Professor Herbie Newell
Professor Alan Calvert
Professor Anne Dickinson
Professor Frederick Campbell
Professor Nicola Curtin
et al.
Dipyridamole potentiates antipurine antifolate activity in the presence of hypoxanthine in tumor cells but not in normal tissues in vitro1998
Professor Alan Calvert
Professor Herbie Newell
Professor Nicola Curtin
Dipyridamole selectively potentiates antipurine antifolates in human tumour cell lines but not normal tissue targets of dose-limiting toxicity1998
Noel Monks
Professor Herbie Newell
Professor Nicola Curtin
Induction of apoptosis in LoVo colorectal cells by the ADEPT system ZD2767: A comparison with chlorambucil and a mono-functional ZD2767 analogue1998
Professor Jane Endicott
Professor Martin Noble
Professor Alan Calvert
Professor Nicola Curtin
Professor Bernard Golding
et al.
Insights into CDK inhibitor design from X-ray crystallographic studies1998
Professor Alan Calvert
Professor Nicola Curtin
Professor Jane Endicott
Professor Bernard Golding
Professor Roger Griffin
et al.
O-6-alkylguanines as selective inhibitors of cyclin dependent kinases1998
Alex White
Professor Bernard Golding
Professor Roger Griffin
Professor Nicola Curtin
Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU10641998
Peter Smith
Professor Herbie Newell
Professor Alan Calvert
Professor Nicola Curtin
Potentiation of the in vitro activity of the multi-targeted antifolate MTA (LY231514) by dipyridamole1998
Professor Roger Griffin
Professor Alan Calvert
Professor Nicola Curtin
Professor Herbie Newell
Professor Bernard Golding
et al.
Resistance-modifying agents. 5.1 Synthesis and biological properties of quinazolinone inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase (PARP)1998
Professor Nicola Curtin
Selective potentiation of lometrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage1997
Professor Nicola Curtin
Dipyridamole increases VP16 growth inhibition, accumulation and retention in parental and multidrug-resistant CHO cells1996
Dr Christine Arris
Dr Christine Bleasdale
Professor Alan Calvert
Professor Nicola Curtin
Professor Bernard Golding
et al.
Mechanism-based inhibition of O-6-methylguanine-DNA methyltransferase.1996
Professor Roger Griffin
Alex White
Kenneth Bowman
Professor Alan Calvert
Professor Nicola Curtin
et al.
Novel benzimidazole and quinazolinone inhibitors of the DNA repair enzyme Poly(ADP-ribose)polymerase1996
Professor Roger Griffin
Professor Nicola Curtin
Professor Herbie Newell
Professor Bernard Golding
Professor barbara Durkacz
et al.
The Role of Inhibitors of Poly(Adp-Ribose) Polymerase as Resistance-Modifying Agents in Cancer-Therapy1995
Dr Christine Arris
Dr Christine Bleasdale
Professor Alan Calvert
Professor Nicola Curtin
Professor Bernard Golding
et al.
Probing the active site and mechanism of action of O-6-methylguanine-DNA methyltransferase with substrate-analogs to (O-6-substituted guanines)1994
Professor Nicola Curtin
Mechanism of cell-death following thymidylate synthase inhibition - 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth-inhibition following exposure to CB3717 and dipyridamole.1991
Professor Nicola Curtin
Dipyridamole enhances increased intracellular DUTP and DNA strand breakage in A549 (human lung-carcinoma) cells treated with CB37171990
Professor Nicola Curtin
A radioimmunoassay for deoxythymidine triphosphate1989
Professor Nicola Curtin
Professor Herbie Newell
Modulation of dipyridamole action by alpha 1 acid glycoprotein. Reduced potentiation of quinazoline antifolate (CB3717) cytotoxicity by dipyridamole.1989
Professor Nicola Curtin
The quantitation by radioimmunoassay of 2'-deoxyuridine 5'-triphosphate in extracts of thymidylate synthase-inhabited cells1989
Professor Nicola Curtin
Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells.1988
Professor Margaret Bassendine
Professor Nicola Curtin
Dr Henry Loose
Emeritus Professor Oliver James
Induction of remission in hepatocellular carcinoma with a new thymidylate synthase inhibitor, CB3717. A phase II study.1987
Professor Nicola Curtin
The quantification of 2'-deoxyuridine 5'-triphosphate in antifolate treated cells using a sensitive radioimmunoassay1987
Professor Margaret Bassendine
Professor Nicola Curtin
Emeritus Professor Oliver James
A new thymidylate synthase (TS) inhibitor, CB3717, in human primary liver cancer (PLC) - invitro, xenograft and phase-II studies1986
Professor Margaret Bassendine
Professor Nicola Curtin
Emeritus Professor Oliver James
Induction of remission in primary liver cell cancer PLC with a new thymidylate synthase inhibitor, CB3717: a phase II study1986
Professor Nicola Curtin
Emeritus Professor Oliver James
Professor Margaret Bassendine
Inhibition of the growth of human hepatocellular-carcinoma invitro and in athymic mice by a quinazoline inhibitor of thymidylate suntjase, CB37171986
Emeritus Professor Oliver James
Professor Nicola Curtin
Professor Margaret Bassendine
Primary hepatocellular carcinoma localised by a radiolabelled monoclonal antibody1986
Emeritus Professor Oliver James
Professor Margaret Bassendine
Professor Nicola Curtin
Localization of primary hepatocellular carcinoma by a radiolabeled monoclonal antibody1985
Emeritus Professor Oliver James
Professor Margaret Bassendine
Professor Nicola Curtin
Primary hepatocellular carcinoma localization using a radiolabeled monoclonal antibody1985
Professor Margaret Bassendine
Emeritus Professor Oliver James
Professor Nicola Curtin
Localization of primary hepatocellular carcinoma using a radiolabeled monoclonal antibody1984
Professor Nicola Curtin
Enzymic retrodifferentiation during hepatocarcinogenesis and liver regeneration in rats in vivo1983
Professor Margaret Bassendine
Professor Nicola Curtin
Emeritus Professor Oliver James
Successful treatment of human primary liver cancer xenograft by new quinazoline anti folate agent CB 37171983
Professor Nicola Curtin
Changes in developmental-specific enzyme activities during experimental hepatocarcinogenesis in the rat in vivo1980
Professor Nicola Curtin
Effect of chronic N,N-diethylnitrosamine on the excision of O6-ethylguanine from rat liver DNA1979